[Update on the use of estramustin in metastatic prostate cancer].
Chemotherapy is indicated in metastatic castration-refractory prostate cancer. It aims at alleviating symptoms and increasing survival, without impairing quality of life. Docetaxel is considered as the reference treatment in this indication. However, several studies demonstrated the relevance of associating estramustin with docetaxel, due to the synergistic effect of the combination and the action of estramustin on resistance mechanisms. Moreover, the addition of estramustin to chemotherapy demonstrated a survival benefit for patients. Thrombotic events are frequent in patients with advanced prostate cancer and estramustine is known to increase the risk. Optimization of treatment requires a thorough assessment of the individual risk in each patient as well as the prescription of an anti-thrombotic prophylaxis, which should be currently based on low molecular weight heparin.
Culine
S
S
Service oncologie médicale, hôpital Henri-Mondor, université Paris XII, Créteil, France.
Drouet
L
L
Eymard
J-C
JC
Fizazi
K
K
Gravis
G
G
Hennequin
C
C
Oudard
S
S
Ravery
V
V
Zerbib
M
M
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004961:Estramustine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000473:pathology*
D018931:Antineoplastic Agents, Hormonal; D004961:Estramustine